Emerging Developments of Chemoradiotherapy in Stage III NSCLC

Overview

Journal Nat Rev Clin Oncol

Specialty Oncology

Date 2012 Aug 29

PMID 22926022

Citations 11

Authors

Allan Price

Affiliations

Soon will be listed here.

Abstract

Over the past decade, concomitant chemotherapy and radiotherapy has become the established treatment for patients with stage III non-small-cell lung cancer (NSCLC). Unfortunately, many patients with NSCLC are too old or have multiple comorbidities to withstand such aggressive treatments. Attempts to improve outcomes have included studies of radiotherapy dose escalation and new chemotherapy combinations, as well as adding biological agents and cancer vaccines to existing regimens. Technical radiotherapy modifications, including intensity-modulated radiotherapy and particle beam therapy, have also been investigated. Given the number of potential advances to current models of treatment development, phase III trials of any single new treatment can take years to complete, which is inadequate. To advance research within shorter timescales to improve patient outcomes, we need methods of improving clinical trial accrual, which might require changes in models of research governance, cooperative group activity, trial design and patient consent.

Citing Articles

Efficacy and safety of neoadjuvant chemoimmunotherapy and chemotherapy in patients with potentially resectable stage IIIA/IIIB NSCLC: a retrospective study.

Wang Y, Ma X, Ma K, Chen X, He H, Zhao X Front Immunol. 2025; 15:1479263.

PMID: 39896808 PMC: 11782129. DOI: 10.3389/fimmu.2024.1479263.

A survival nomogram model for patients with resectable non-small cell lung cancer and lymph node metastasis (N1 or N2) based on the Surveillance, Epidemiology, and End Results Database and single-center data.

He C, Ni M, Liu J, Teng X, Ke L, Matsuura Y Transl Lung Cancer Res. 2024; 13(3):573-586.

PMID: 38601448 PMC: 11002513. DOI: 10.21037/tlcr-24-119.

Identification of Radiotherapy-Associated Genes in Lung Adenocarcinoma by an Integrated Bioinformatics Analysis Approach.

Wang J, Han Q, Liu H, Luo H, Li L, Liu A Front Mol Biosci. 2021; 8:624575.

PMID: 34212001 PMC: 8239180. DOI: 10.3389/fmolb.2021.624575.

Oral vinorelbine plus cisplatin with concomitant radiotherapy as induction therapy for stage III non-small cell lung cancer: Results of a single-arm prospective cohort study.

Hsu P, Chang J, Wang C, Wu C, Lin Y, Wang C Thorac Cancer. 2019; 10(8):1683-1691.

PMID: 31276309 PMC: 6669803. DOI: 10.1111/1759-7714.13125.

Combined treatment for non-small cell lung cancer and breast cancer patients with brain metastases with whole brain radiotherapy and temozolomide: a systematic review and meta-analysis.

Tian J, Luo Y, Xiang J, Tang J J Neurooncol. 2017; 135(2):217-227.

PMID: 28726172 DOI: 10.1007/s11060-017-2572-z.

References

Spigel D, Hainsworth J, Yardley D, Raefsky E, Patton J, Peacock N . Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol. 2009; 28(1):43-8. DOI: 10.1200/JCO.2009.24.7353. View

Kratz J, He J, Van Den Eeden S, Zhu Z, Gao W, Pham P . A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet. 2012; 379(9818):823-32. PMC: 3294002. DOI: 10.1016/S0140-6736(11)61941-7. View

Lind J, Senan S, Smit E . Pulmonary toxicity after bevacizumab and concurrent thoracic radiotherapy observed in a phase I study for inoperable stage III non-small-cell lung cancer. J Clin Oncol. 2012; 30(8):e104-8. DOI: 10.1200/JCO.2011.38.4552. View

Nieder C, Pawinski A, Dalhaug A, Andratschke N . A review of clinical trials of cetuximab combined with radiotherapy for non-small cell lung cancer. Radiat Oncol. 2012; 7:3. PMC: 3269364. DOI: 10.1186/1748-717X-7-3. View

Stinchcombe T, Hodgson L, Herndon 2nd J, Kelley M, Cicchetti M, Ramnath N . Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer. J Thorac Oncol. 2009; 4(9):1117-25. PMC: 2778485. DOI: 10.1097/JTO.0b013e3181b27b33. View

Segawa Y, Kiura K, Takigawa N, Kamei H, Harita S, Hiraki S . Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin Oncol. 2010; 28(20):3299-306. DOI: 10.1200/JCO.2009.24.7577. View

De Ruysscher D, van Baardwijk A, Steevens J, Botterweck A, Bosmans G, Reymen B . Individualised isotoxic accelerated radiotherapy and chemotherapy are associated with improved long-term survival of patients with stage III NSCLC: a prospective population-based study. Radiother Oncol. 2011; 102(2):228-33. DOI: 10.1016/j.radonc.2011.10.010. View

Vokes E, Herndon 2nd J, Kelley M, Cicchetti M, Ramnath N, Neill H . Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol. 2007; 25(13):1698-704. DOI: 10.1200/JCO.2006.07.3569. View

Baumann M, Herrmann T, Koch R, Matthiessen W, Appold S, Wahlers B . Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC). Radiother Oncol. 2011; 100(1):76-85. DOI: 10.1016/j.radonc.2011.06.031. View

10.

Mutter R, Lu B, Carbone D, Csiki I, Moretti L, Johnson D . A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer. Clin Cancer Res. 2009; 15(6):2158-65. DOI: 10.1158/1078-0432.CCR-08-0629. View

11.

Salama J, Stinchcombe T, Gu L, Wang X, Morano K, Bogart J . Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and.... Int J Radiat Oncol Biol Phys. 2011; 81(4):e269-74. PMC: 3135692. DOI: 10.1016/j.ijrobp.2011.01.056. View

12.

Kelly K, Chansky K, Gaspar L, Albain K, Jett J, Ung Y . Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol. 2008; 26(15):2450-6. DOI: 10.1200/JCO.2007.14.4824. View

13.

Robinson L, Ruckdeschel J, Wagner Jr H, Stevens C . Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007; 132(3 Suppl):243S-265S. DOI: 10.1378/chest.07-1379. View

14.

Fenwick J, Nahum A, Malik Z, Eswar C, Hatton M, Laurence V . Escalation and intensification of radiotherapy for stage III non-small cell lung cancer: opportunities for treatment improvement. Clin Oncol (R Coll Radiol). 2009; 21(4):343-60. DOI: 10.1016/j.clon.2008.12.011. View

15.

Yamamoto N, Nakagawa K, Nishimura Y, Tsujino K, Satouchi M, Kudo S . Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol. 2010; 28(23):3739-45. DOI: 10.1200/JCO.2009.24.5050. View

16.

Jalal S, Riggs H, Melnyk A, Richards D, Agarwala A, Neubauer M . Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the.... Ann Oncol. 2011; 23(7):1730-8. DOI: 10.1093/annonc/mdr565. View

17.

Socinski M, Blackstock A, Bogart J, Wang X, Munley M, Rosenman J . Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol. 2008; 26(15):2457-63. DOI: 10.1200/JCO.2007.14.7371. View

18.

Govindan R, Bogart J, Stinchcombe T, Wang X, Hodgson L, Kratzke R . Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. J Clin Oncol. 2011; 29(23):3120-5. PMC: 3157978. DOI: 10.1200/JCO.2010.33.4979. View

19.

van Baardwijk A, Wanders S, Boersma L, Borger J, Ollers M, Dingemans A . Mature results of an individualized radiation dose prescription study based on normal tissue constraints in stages I to III non-small-cell lung cancer. J Clin Oncol. 2010; 28(8):1380-6. DOI: 10.1200/JCO.2009.24.7221. View

20.

Lee C, Stinchcombe T, Moore D, Morris D, Hayes D, Halle J . Late complications of high-dose (>/=66 Gy) thoracic conformal radiation therapy in combined modality trials in unresectable stage III non-small cell lung cancer. J Thorac Oncol. 2008; 4(1):74-9. DOI: 10.1097/JTO.0b013e3181915028. View